CBOE Holdings Inc.

06/11/2019 | Press release | Distributed by Public on 06/11/2019 07:38

Denali Therapeutics Receives Orphan Drug And Rare Pediatric Disease Designation For DNL310, And Expands Its Portfolio Of Brain Penetrant Enzyme Replacement Programs

Cboe - Market News Story

Denali Therapeutics Receives Orphan Drug And Rare Pediatric Disease Designation For DNL310, And Expands Its Portfolio Of Brain Penetrant Enzyme Replacement Programs

Benzinga Newsdesk 6/11/2019 8:03:04 AM

-Reuters